{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:44:01Z","timestamp":1792626241488,"version":"4.5.0"},"reference-count":159,"publisher":"Bentham Science Publishers Ltd.","issue":"11","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>The purinergic P2X7 receptor (P2X7R), an ATP-gated non-selective cation\nchannel, has emerged as a gatekeeper of inflammation that controls the release of proinflammatory\ncytokines. As a key player in initiating the inflammatory signaling cascade,\nthe P2X7 receptor is currently under intense scrutiny as a target for the treatment of different\npathologies, including chronic inflammatory disorders (rheumatoid arthritis and osteoarthritis),\nchronic neuropathic pain, mood disorders (depression and anxiety), neurodegenerative\ndiseases, ischemia, cancer (leukemia), and many others. For these reasons,\npharmaceutical companies have invested in discovering compounds able to modulate the\nP2X7R and filed many patent applications. This review article presents an account of\nP2X7R structure, function, and tissue distribution, emphasizing its role in inflammation.\nNext, we illustrate the different chemical classes of non-competitive P2X7R antagonists\nreported by highlighting their properties and qualities as clinical candidates for treating inflammatory\ndisorders and neurodegenerative diseases. We also discuss the efforts to develop\neffective Positron Emission Tomography (PET) radioligands to progress the understanding\nof the pathomechanisms of neurodegenerative disorders, to provide evidence of\ndrug-target engagement, and to assist clinical dose selection for novel drug therapies.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867330666230403094538","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T05:30:01Z","timestamp":1680586201000},"page":"1361-1403","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Structure-Activity Relationships and Therapeutic Potential of\nPurinergic P2X7 Receptor Antagonists"],"prefix":"10.2174","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6388-6265","authenticated-orcid":true,"given":"Imane","family":"Ghafir El Idrissi","sequence":"first","affiliation":[{"name":"Dipartimento di Farmacia - Scienze del Farmaco, Universit\u00e0 degli Studi di Bari Aldo Moro, via Orabona,\nBari, 470125, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2891-5603","authenticated-orcid":true,"given":"Sabina","family":"Podlewska","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Krak\u00f3w, 12 Sm\u0119tna Street, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9292-884X","authenticated-orcid":true,"given":"Carmen","family":"Abate","sequence":"additional","affiliation":[{"name":"Dipartimento di Farmacia - Scienze del Farmaco, Universit\u00e0 degli Studi di Bari Aldo Moro, via Orabona,\nBari, 470125, Italy"},{"name":"Consiglio Nazionale delle Ricerche (CNR), Istituto di\nCristallografia, via Amendola, Bari, 70125, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1417-6333","authenticated-orcid":true,"given":"Andrzej J.","family":"Bojarski","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Krak\u00f3w, 12 Sm\u0119tna Street, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2443-1174","authenticated-orcid":true,"given":"Enza","family":"Lacivita","sequence":"additional","affiliation":[{"name":"Dipartimento di Farmacia - Scienze del Farmaco, Universit\u00e0 degli Studi di Bari Aldo Moro, via Orabona,\nBari, 470125, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8401-2815","authenticated-orcid":true,"given":"Marcello","family":"Leopoldo","sequence":"additional","affiliation":[{"name":"Dipartimento di Farmacia - Scienze del Farmaco, Universit\u00e0 degli Studi di Bari Aldo Moro, via Orabona,\nBari, 470125, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1152\/physrev.00015.2002","volume":"82","author":"North R.A.","year":"2002","unstructured":"North R.A.; Molecular physiology of P2X receptors. Physiol Rev  2002,82(4),1013-1067","journal-title":"Physiol Rev"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/0306-3623(85)90001-1","volume":"16","author":"Burnstock G.","year":"1985","unstructured":"Burnstock G.; Kennedy C.; Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol  1985,16(5),433-440","journal-title":"Gen Pharmacol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bmc.2013.10.054","volume":"22","author":"Mehta N.","year":"2014","unstructured":"Mehta N.; Kaur M.; Singh M.; Chand S.; Vyas B.; Silakari P.; Bahia M.S.; Silakari O.; Purinergic receptor P2X7: A novel target for anti-inflammatory therapy. Bioorg Med Chem  2014,22(1),54-88","journal-title":"Bioorg Med Chem"},{"key":"ref=4","first-page":"16","volume":"1","author":"Syed N.H.","year":"2012","unstructured":"Syed N.H.; Kennedy C.; Pharmacology of P2X receptors. WIREs Membr. Transp Signal  2012,1,16-30","journal-title":"Transp Signal"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"662935","DOI":"10.3389\/fncel.2021.662935","volume":"15","author":"Oliveira-Giacomelli \u00c1.","year":"2021","unstructured":"Oliveira-Giacomelli \u00c1.; Petiz L.L.; Andrejew R.; Turrini N.; Silva J.B.; Sack U.; Ulrich H.; Role of P2X7 receptors in immune responses during neurodegeneration. Front Cell Neurosci  2021,15,662935","journal-title":"Front Cell Neurosci"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nri2938","volume":"11","author":"Junger W.G.","year":"2011","unstructured":"Junger W.G.; Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol  2011,11(3),201-212","journal-title":"Nat Rev Immunol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s002329900298","volume":"160","author":"Soto F.","year":"1997","unstructured":"Soto F.; Garcia-Guzman M.; St\u00fchmer W.; Cloned ligand-gated channels activated by extracellular ATP (P2X receptors). J Membr Biol  1997,160(2),91-100","journal-title":"J Membr Biol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1124\/pr.110.003129","volume":"63","author":"Coddou C.","year":"2011","unstructured":"Coddou C.; Yan Z.; Obsil T.; Huidobro-Toro J.P.; Stojilkovic S.S.; Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev  2011,63(3),641-683","journal-title":"Pharmacol Rev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/5584_2017_59","volume":"1051","author":"Sluyter R.","year":"2017","unstructured":"Sluyter R.; The P2X7 receptor. Adv Exp Med Biol  2017,1051,17-53","journal-title":"Adv Exp Med Biol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","volume":"47","author":"Di Virgilio F.","year":"2017","unstructured":"Di Virgilio F.; Dal Ben D.; Sarti A.C.; Giuliani A.L.; Falzoni S.; The P2X7 receptor in infection and inflammation. Immunity  2017,47(1),15-31","journal-title":"Immunity"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fphar.2013.00055","volume":"4","author":"Jiang L.H.","year":"2013","unstructured":"Jiang L.H.; Baldwin J.M.; Roger S.; Baldwin S.A.; Insights into the molecular mechanisms underlying mammalian P2X7 receptor functions and contributions in diseases, revealed by structural modeling and single nucleotide polymorphisms. Front Pharmacol  2013,4,55","journal-title":"Front Pharmacol"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jpsychires.2009.10.005","volume":"44","author":"Roger S.","year":"2010","unstructured":"Roger S.; Mei Z.Z.; Baldwin J.M.; Dong L.; Bradley H.; Baldwin S.A.; Surprenant A.; Jiang L.H.; Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. J Psychiatr Res  2010,44(6),347-355","journal-title":"J Psychiatr Res"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11302-009-9136-4","volume":"5","author":"Fuller S.J.","year":"2009","unstructured":"Fuller S.J.; Stokes L.; Skarratt K.K.; Gu B.J.; Wiley J.S.; Genetics of the P2X7 receptor and human disease. Purinergic Signal  2009,5(2),257-262","journal-title":"Purinergic Signal"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.pneurobio.2006.03.007","volume":"78","author":"Sperl\u00e1gh B.","year":"2006","unstructured":"Sperl\u00e1gh B.; Vizi E.; Wirkner K.; Illes P.; P2X7 receptors in the nervous system. Prog Neurobiol  2006,78(6),327-346","journal-title":"Prog Neurobiol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s12026-011-8203-4","volume":"50","author":"Lenertz L.Y.","year":"2011","unstructured":"Lenertz L.Y.; Gavala M.L.; Zhu Y.; Bertics P.J.; Transcriptional control mechanisms associated with the nucleotide receptor P2X7, a critical regulator of immunologic, osteogenic, and neurologic functions. Immunol Res  2011,50(1),22-38","journal-title":"Immunol Res"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1399-0039.2011.01780.x","volume":"78","author":"Wiley J.S.","year":"2011","unstructured":"Wiley J.S.; Sluyter R.; Gu B.J.; Stokes L.; Fuller S.J.; The human P2X7 receptor and its role in innate immunity. Tissue Antigens  2011,78(5),321-332","journal-title":"Tissue Antigens"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"6653","DOI":"10.1074\/jbc.274.10.6653","volume":"274","author":"Torres G.E.","year":"1999","unstructured":"Torres G.E.; Egan T.M.; Voigt M.M.; Hetero-oligomeric assembly of P2X receptor subunits. Specificities exist with regard to possible partners. J Biol Chem  1999,274(10),6653-6659","journal-title":"J Biol Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.bbrc.2008.10.042","volume":"377","author":"Nicke A.","year":"2008","unstructured":"Nicke A.; Homotrimeric complexes are the dominant assembly state of native P2X7 subunits. Biochem Biophys Res Commun  2008,377(3),803-808","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nature08198","volume":"460","author":"Kawate T.","year":"2009","unstructured":"Kawate T.; Michel J.C.; Birdsong W.T.; Gouaux E.; Crystal structure of the ATP-gated P2X4 ion channel in the closed state. Nature  2009,460(7255),592-598","journal-title":"Nature"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.neuropharm.2015.07.032","volume":"104","author":"Habermacher C.","year":"2016","unstructured":"Habermacher C.; Dunning K.; Chataigneau T.; Grutter T.; Molecular structure and function of P2X receptors. Neuropharmacology  2016,104,18-30","journal-title":"Neuropharmacology"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/j.cell.2019.09.017","volume":"179","author":"McCarthy A.E.","year":"2019","unstructured":"McCarthy A.E.; Yoshioka C.; Mansoor S.E.; Full-Length P2X7 structures reveal how palmitoylation prevents channel desensitization. Cell  2019,179(3),659-670.e13","journal-title":"Cell"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s11302-011-9255-6","volume":"7","author":"Costa-Junior H.M.","year":"2011","unstructured":"Costa-Junior H.M.; Marques-da-Silva C.; Vieira F.S.; Mon\u00e7\u00e3o-Ribeiro L.C.; Coutinho-Silva R.; Lipid metabolism modulation by the P2X7 receptor in the immune system and during the course of infection: new insights into the old view. Purinergic Signal  2011,7(4),381-392","journal-title":"Purinergic Signal"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"3231","DOI":"10.1038\/s41598-019-39771-5","volume":"9","author":"Bidula S.M.","year":"2019","unstructured":"Bidula S.M.; Cromer B.A.; Walpole S.; Angulo J.; Stokes L.; Mapping a novel positive allosteric modulator binding site in the central vestibule region of human P2X7. Sci Rep  2019,9(1),3231","journal-title":"Sci Rep"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1124\/mol.119.116715","volume":"96","author":"Bin Dayel A.","year":"2019","unstructured":"Bin Dayel A.; Evans R.J.; Schmid R.; Mapping the site of action of human P2X7 receptor antagonists AZ11645373, brilliant blue G, KN-62, calmidazolium, and ZINC58368839 to the intersubunit allosteric pocket. Mol Pharmacol  2019,96(3),355-363","journal-title":"Mol Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1016\/j.bmcl.2015.06.001","volume":"25","author":"Caseley E.A.","year":"2015","unstructured":"Caseley E.A.; Muench S.P.; Baldwin S.A.; Simmons K.; Fishwick C.W.; Jiang L.H.; Docking of competitive inhibitors to the P2X7 receptor family reveals key differences responsible for changes in response between rat and human. Bioorg Med Chem Lett  2015,25(16),3164-3167","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"e22153","DOI":"10.7554\/eLife.22153","volume":"5","author":"Karasawa A.","year":"2016","unstructured":"Karasawa A.; Kawate T.; Structural basis for subtype-specific inhibition of the P2X7 receptor. eLife  2016,5,e22153","journal-title":"eLife"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1126\/science.272.5262.735","volume":"272","author":"Surprenant A.","year":"1996","unstructured":"Surprenant A.; Rassendren F.; Kawashima E.; North R.A.; Buell G.; The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science  1996,272(5262),735-738","journal-title":"Science"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/nm.2242","volume":"16","author":"Wilhelm K.","year":"2010","unstructured":"Wilhelm K.; Ganesan J.; M\u00fcller T.; D\u00fcrr C.; Grimm M.; Beilhack A.; Krempl C.D.; Sorichter S.; Gerlach U.V.; J\u00fcttner E.; Zerweck A.; G\u00e4rtner F.; Pellegatti P.; Di Virgilio F.; Ferrari D.; Kambham N.; Fisch P.; Finke J.; Idzko M.; Zeiser R.; Graft-versus-host disease is enhanced by extracellular ATP activating P2X7R. Nat Med  2010,16(12),1434-1438","journal-title":"Nat Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/nature04886","volume":"442","author":"Khakh B.S.","year":"2006","unstructured":"Khakh B.S.; Alan North R.; P2X receptors as cell-surface ATP sensors in health and disease. Nature  2006,442(7102),527-532","journal-title":"Nature"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"e2599","DOI":"10.1371\/journal.pone.0002599","volume":"3","author":"Pellegatti P.","year":"2008","unstructured":"Pellegatti P.; Raffaghello L.; Bianchi G.; Piccardi F.; Pistoia V.; Di Virgilio F.; Increased level of extracellular ATP at tumor sites: In vivo imaging with plasma membrane luciferase. PLoS One  2008,3(7),e2599","journal-title":"PLoS One"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2322","DOI":"10.1056\/NEJMra1205750","volume":"367","author":"Eltzschig H.K.","year":"2012","unstructured":"Eltzschig H.K.; Sitkovsky M.V.; Robson S.C.; Purinergic signaling during inflammation. N Engl J Med  2012,367(24),2322-2333","journal-title":"N Engl J Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1074\/jbc.272.9.5482","volume":"272","author":"Rassendren F.","year":"1997","unstructured":"Rassendren F.; Buell G.N.; Virginio C.; Collo G.; North R.A.; Surprenant A.; The permeabilizing ATP receptor, P2X7. Cloning and expression of a human cDNA. J Biol Chem  1997,272(9),5482-5486","journal-title":"J Biol Chem"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/S0014-5793(98)01332-5","volume":"439","author":"Chessell I.P.","year":"1998","unstructured":"Chessell I.P.; Simon J.; Hibell A.D.; Michel A.D.; Barnard E.A.; Humphrey P.P.A.; Cloning and functional characterisation of the mouse P2X 7 receptor. FEBS Lett  1998,439(1-2),26-30","journal-title":"FEBS Lett"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.bcp.2017.12.021","volume":"151","author":"Adinolfi E.","year":"2018","unstructured":"Adinolfi E.; Giuliani A.L.; De Marchi E.; Pegoraro A.; Orioli E.; Di Virgilio F.; The P2X7 receptor: A main player in inflammation. Biochem Pharmacol  2018,151,234-244","journal-title":"Biochem Pharmacol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11302-006-9048-5","volume":"3","author":"Di Virgilio F.","year":"2007","unstructured":"Di Virgilio F.; Purinergic signalling in the immune system. A brief update. Purinergic Signal  2007,3(1-2),1-3","journal-title":"Purinergic Signal"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s11302-013-9357-4","volume":"9","author":"Jacob F.","year":"2013","unstructured":"Jacob F.; Novo C.P.; Bachert C.; Van Crombruggen K.; Purinergic signaling in inflammatory cells: P2 receptor expression, functional effects, and modulation of inflammatory responses. Purinergic Signal  2013,9(3),285-306","journal-title":"Purinergic Signal"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.3892\/ijmm.2015.2129","volume":"35","author":"Peng K.","year":"2015","unstructured":"Peng K.; Liu L.; Wei D.; Lv Y.; Wang G.; Xiong W.; Wang X.; Altaf A.; Wang L.; He D.; Wang H.; Qu P.; P2X7R is involved in the progression of atherosclerosis by promoting NLRP3 inflammasome activation. Int J Mol Med  2015,35(5),1179-1188","journal-title":"Int J Mol Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/1476-9255-4-5","volume":"4","author":"Lister M.F.","year":"2007","unstructured":"Lister M.F.; Sharkey J.; Sawatzky D.A.; Hodgkiss J.P.; Davidson D.J.; Rossi A.G.; Finlayson K.; The role of the purinergic P2X7 receptor in inflammation. J Inflamm  2007,4(1),5","journal-title":"J Inflamm"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11302-009-9133-7","volume":"5","author":"Lenertz L.Y.","year":"2009","unstructured":"Lenertz L.Y.; Gavala M.L.; Hill L.M.; Bertics P.J.; Cell signaling via the P2X7 nucleotide receptor: Linkage to ROS production, gene transcription, and receptor trafficking. Purinergic Signal  2009,5(2),175-187","journal-title":"Purinergic Signal"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.4049\/jimmunol.1203262","volume":"190","author":"Apolloni S.","year":"2013","unstructured":"Apolloni S.; Parisi C.; Pesaresi M.G.; Rossi S.; Carr\u00ec M.T.; Cozzolino M.; Volont\u00e9 C.; D\u2019Ambrosi N.; The NADPH oxidase pathway is dysregulated by the P2X7 receptor in the SOD1-G93A microglia model of amyotrophic lateral sclerosis. J Immunol  2013,190(10),5187-5195","journal-title":"J Immunol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s11302-012-9335-2","volume":"9","author":"Wang B.","year":"2013","unstructured":"Wang B.; Sluyter R.; P2X7 receptor activation induces reactive oxygen species formation in erythroid cells. Purinergic Signal  2013,9(1),101-112","journal-title":"Purinergic Signal"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1600-065X.2011.01046.x","volume":"243","author":"Gross O.","year":"2011","unstructured":"Gross O.; Thomas C.J.; Guarda G.; Tschopp J.; The inflammasome: An integrated view. Immunol Rev  2011,243(1),136-151","journal-title":"Immunol Rev"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1002\/eji.201141436","volume":"41","author":"Tschopp J.","year":"2011","unstructured":"Tschopp J.; Mitochondria: Sovereign of inflammation? Eur J Immunol  2011,41(5),1196-1202","journal-title":"Eur J Immunol"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"e70210","DOI":"10.1371\/journal.pone.0070210","volume":"8","author":"Hung S.C.","year":"2013","unstructured":"Hung S.C.; Choi C.H.; Said-Sadier N.; Johnson L.; Atanasova K.R.; Sellami H.; Yilmaz \u00d6.; Ojcius D.M.; P2X4 assembles with P2X7 and pannexin-1 in gingival epithelial cells and modulates ATP-induced reactive oxygen species production and inflammasome activation. PLoS One  2013,8(7),e70210","journal-title":"PLoS One"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/glia.22499","volume":"61","author":"Minkiewicz J.","year":"2013","unstructured":"Minkiewicz J.; de Rivero Vaccari J.P.; Keane R.W.; Human astrocytes express a novel NLRP2 inflammasome. Glia  2013,61(7),1113-1121","journal-title":"Glia"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"4378","DOI":"10.4049\/jimmunol.0803612","volume":"182","author":"Sanz J.M.","year":"2009","unstructured":"Sanz J.M.; Chiozzi P.; Ferrari D.; Colaianna M.; Idzko M.; Falzoni S.; Fellin R.; Trabace L.; Di Virgilio F.; Activation of microglia by amyloid beta requires P2X7 receptor expression. J Immunol  2009,182(7),4378-4385","journal-title":"J Immunol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.neuropharm.2017.10.027","volume":"128","author":"S\u00e1ez-Orellana F.","year":"2018","unstructured":"S\u00e1ez-Orellana F.; Fuentes-Fuentes M.C.; Godoy P.A.; Silva-Grecchi T.; Panes J.D.; Guzm\u00e1n L.; Y\u00e9venes G.E.; Gavil\u00e1n J.; Egan T.M.; Aguayo L.G.; Fuentealba J.; P2X receptor overexpression induced by soluble oligomers of amyloid beta peptide potentiates synaptic failure and neuronal dyshomeostasis in cellular models of Alzheimer\u2019s disease. Neuropharmacology  2018,128,366-378","journal-title":"Neuropharmacology"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"13309","DOI":"10.1074\/jbc.M209478200","volume":"278","author":"Parvathenani L.K.","year":"2003","unstructured":"Parvathenani L.K.; Tertyshnikova S.; Greco C.R.; Roberts S.B.; Robertson B.; Posmantur R.; P2X7 mediates superoxide production in primary microglia and is up-regulated in a transgenic mouse model of Alzheimer\u2019s disease. J Biol Chem  2003,278(15),13309-13317","journal-title":"J Biol Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1097\/01.jnen.0000240470.97295.d3","volume":"65","author":"McLarnon J.G.","year":"2006","unstructured":"McLarnon J.G.; Ryu J.K.; Walker D.G.; Choi H.B.; Upregulated expression of purinergic P2X(7) receptor in Alzheimer disease and amyloid-beta peptide-treated microglia and in peptide-injected rat hippocampus. J Neuropathol Exp Neurol  2006,65(11),1090-1097","journal-title":"J Neuropathol Exp Neurol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1097\/WNR.0b013e3283179333","volume":"19","author":"Ryu J.K.","year":"2008","unstructured":"Ryu J.K.; McLarnon J.G.; Block of purinergic P2X7 receptor is neuroprotective in an animal model of Alzheimer\u2019s disease. Neuroreport  2008,19(17),1715-1719","journal-title":"Neuroreport"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/214714","volume":"2012","author":"Durrenberger P.F.","year":"2012","unstructured":"Durrenberger P.F.; Gr\u00fcnblatt E.; Fernando F.S.; Monoranu C.M.; Evans J.; Riederer P.; Reynolds R.; Dexter D.T.; Inflammatory pathways in Parkinson\u2019s disease; a BNE microarray study. Parkinsons Dis  2012,2012,1-16","journal-title":"Parkinsons Dis"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/j.neurobiolaging.2015.03.015","volume":"36","author":"Jiang T.","year":"2015","unstructured":"Jiang T.; Hoekstra J.; Heng X.; Kang W.; Ding J.; Liu J.; Chen S.; Zhang J.; P2X7 receptor is critical in \u03b1-synuclein\u2013mediated microglial NADPH oxidase activation. Neurobiol Aging  2015,36(7),2304-2318","journal-title":"Neurobiol Aging"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.neuropharm.2014.01.045","volume":"81","author":"Carmo M.R.S.","year":"2014","unstructured":"Carmo M.R.S.; Menezes A.P.F.; Nunes A.C.L.; Pli\u00e1ssova A.; Rolo A.P.; Palmeira C.M.; Cunha R.A.; Canas P.M.; Andrade G.M.; The P2X7 receptor antagonist Brilliant Blue G attenuates contralateral rotations in a rat model of Parkinsonism through a combined control of synaptotoxicity, neurotoxicity and gliosis. Neuropharmacology  2014,81,142-152","journal-title":"Neuropharmacology"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1007\/s11064-017-2383-9","volume":"42","author":"Kumar S.","year":"2017","unstructured":"Kumar S.; Mishra A.; Krishnamurthy S.; Purinergic antagonism prevents mitochondrial dysfunction and behavioral deficits associated with dopaminergic toxicity induced by 6-OHDA in rats. Neurochem Res  2017,42(12),3414-3430","journal-title":"Neurochem Res"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3389\/fphar.2020.01148","volume":"11","author":"Volont\u00e9 C.","year":"2020","unstructured":"Volont\u00e9 C.; Amadio S.; Liguori F.; Fabbrizio P.; Duality of P2X7 receptor in amyotrophic lateral sclerosis. Front Pharmacol  2020,11,1148","journal-title":"Front Pharmacol"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1111\/bpa.12774","volume":"30","author":"Fabbrizio P.","year":"2020","unstructured":"Fabbrizio P.; Apolloni S.; Bianchi A.; Salvatori I.; Valle C.; Lanzuolo C.; Bendotti C.; Nardo G.; Volont\u00e9 C.; P2X7 activation enhances skeletal muscle metabolism and regeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis. Brain Pathol  2020,30(2),272-282","journal-title":"Brain Pathol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2377-6-12","volume":"6","author":"Yiangou Y.","year":"2006","unstructured":"Yiangou Y.; Facer P.; Durrenberger P.; Chessell I.P.; Naylor A.; Bountra C.; Banati R.R.; Anand P.; COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells\/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol  2006,6(1),12","journal-title":"BMC Neurol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s12883-021-02288-4","volume":"21","author":"Nukui T.","year":"2021","unstructured":"Nukui T.; Matsui A.; Niimi H.; Sugimoto T.; Hayashi T.; Dougu N.; Konishi H.; Yamamoto M.; Anada R.; Matsuda N.; Kitajima I.; Nakatsuji Y.; Increased cerebrospinal fluid adenosine 5\u2032-triphosphate in patients with amyotrophic lateral sclerosis. BMC Neurol  2021,21(1),255","journal-title":"BMC Neurol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1742-2094-7-33","volume":"7","author":"Gandelman M.","year":"2010","unstructured":"Gandelman M.; Peluffo H.; Beckman J.S.; Cassina P.; Barbeito L.; Extracellular ATP and the P2X7receptor in astrocyte-mediated motor neuron death: Implications for amyotrophic lateral sclerosis. J Neuroinflammation  2010,7(1),33","journal-title":"J Neuroinflammation"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3389\/fncel.2017.00249","volume":"11","author":"Fabbrizio P.","year":"2017","unstructured":"Fabbrizio P.; Amadio S.; Apolloni S.; Volont\u00e9 C.; P2X7 Receptor activation modulates autophagy in SOD1-G93A mouse microglia. Front Cell Neurosci  2017,11,249","journal-title":"Front Cell Neurosci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"9525","DOI":"10.1523\/JNEUROSCI.0579-07.2007","volume":"27","author":"Matute C.","year":"2007","unstructured":"Matute C.; Torre I.; P\u00e9rez-Cerd\u00e1 F.; P\u00e9rez-Samart\u00edn A.; Alberdi E.; Etxebarria E.; Arranz A.M.; Ravid R.; Rodr\u00edguez-Antig\u00fcedad A.; S\u00e1nchez-G\u00f3mez M.; Domercq M.; P2X(7) receptor blockade prevents ATP excitotoxicity in oligodendrocytes and ameliorates experimental autoimmune encephalomyelitis. J Neurosci  2007,27(35),9525-9533","journal-title":"J Neurosci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.3389\/fimmu.2017.01529","volume":"8","author":"Amadio S.","year":"2017","unstructured":"Amadio S.; Parisi C.; Piras E.; Fabbrizio P.; Apolloni S.; Montilli C.; Luchetti S.; Ruggieri S.; Gasperini C.; Laghi-Pasini F.; Battistini L.; Volont\u00e9 C.; Modulation of P2X7 receptor during inflammation in multiple sclerosis. Front Immunol  2017,8,1529","journal-title":"Front Immunol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"108297","DOI":"10.1016\/j.intimp.2021.108297","volume":"101","author":"Cai X.","year":"2021","unstructured":"Cai X.; Yao Y.; Teng F.; Li Y.; Wu L.; Yan W.; Lin N.; The role of P2X7 receptor in infection and metabolism:\tBased on inflammation and immunity. Int. Immunopharmacol.  2021,101(Pt A),108297"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.humimm.2010.05.008","volume":"71","author":"Portales-Cervantes L.","year":"2010","unstructured":"Portales-Cervantes L.; Ni\u00f1o-Moreno P.; Don\u00edz-Padilla L.; Baranda-Candido L.; Garc\u00eda-Hern\u00e1ndez M.; Salgado-Bustamante M.; Gonz\u00e1lez-Amaro R.; Portales-P\u00e9rez D.; Expression and function of the P2X7 purinergic receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. Hum Immunol  2010,71(8),818-825","journal-title":"Hum Immunol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"35804","DOI":"10.1038\/srep35804","volume":"6","author":"Fan Z.D.","year":"2016","unstructured":"Fan Z.D.; Zhang Y.Y.; Guo Y.H.; Huang N.; Ma H.H.; Huang H.; Yu H.G.; Involvement of P2X7 receptor signaling on regulating the differentiation of Th17 cells and type II collagen-induced arthritis in mice. Sci Rep  2016,6(1),35804","journal-title":"Sci Rep"},{"key":"ref=66","first-page":"878","volume":"32","author":"McInnes I.B.","year":"2014","unstructured":"McInnes I.B.; Cruwys S.; Bowers K.; Braddock M.; Targeting the P2X7 receptor in rheumatoid arthritis: Biological rationale for P2X7 antagonism. Clin Exp Rheumatol  2014,32(6),878-882","journal-title":"Clin Exp Rheumatol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.4049\/jimmunol.1000436","volume":"185","author":"Lopez-Castejon G.","year":"2010","unstructured":"Lopez-Castejon G.; Theaker J.; Pelegrin P.; Clifton A.D.; Braddock M.; Surprenant A.; P2X(7) receptor-mediated release of cathepsins from macrophages is a cytokine-independent mechanism potentially involved in joint diseases. J Immunol  2010,185(4),2611-2619","journal-title":"J Immunol"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1097\/01.MIB.0000441201.10454.06","volume":"20","author":"Neves A.R.","year":"2014","unstructured":"Neves A.R.; Castelo-Branco M.T.L.; Figliuolo V.R.; Bernardazzi C.; Buongusto F.; Yoshimoto A.; Nanini H.F.; Coutinho C.M.L.M.; Carneiro A.J.V.; Coutinho-Silva R.; de Souza H.S.P.; Overexpression of ATP-activated P2X7 receptors in the intestinal mucosa is implicated in the pathogenesis of Crohn\u2019s disease. Inflamm Bowel Dis  2014,20(3),444-457","journal-title":"Inflamm Bowel Dis"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"638","DOI":"10.3389\/fphar.2017.00638","volume":"8","author":"Gentile D.","year":"2017","unstructured":"Gentile D.; Lazzerini P.E.; Gamberucci A.; Natale M.; Selvi E.; Vanni F.; Al\u00ec A.; Taddeucci P.; Del-Ry S.; Cabiati M.; Della-Latta V.; Abraham D.J.; Morales M.A.; Fulceri R.; Laghi-Pasini F.; Capecchi P.L.; Searching novel therapeutic targets for scleroderma: P2X7-receptor is upregulated and promotes a fibrogenic phenotype in systemic sclerosis fibroblasts. Front Pharmacol  2017,8,638","journal-title":"Front Pharmacol"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1091\/mbc.e04-11-1025","volume":"16","author":"Adinolfi E.","year":"2005","unstructured":"Adinolfi E.; Callegari M.G.; Ferrari D.; Bolognesi C.; Minelli M.; Wieckowski M.R.; Pinton P.; Rizzuto R.; Di Virgilio F.; Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell  2005,16(7),3260-3272","journal-title":"Mol Biol Cell"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"10120","DOI":"10.1074\/jbc.M805805200","volume":"284","author":"Adinolfi E.","year":"2009","unstructured":"Adinolfi E.; Callegari M.G.; Cirillo M.; Pinton P.; Giorgi C.; Cavagna D.; Rizzuto R.; Di Virgilio F.; Expression of the P2X7 receptor increases the Ca2+ content of the endoplasmic reticulum, activates NFATc1, and protects from apoptosis. J Biol Chem  2009,284(15),10120-10128","journal-title":"J Biol Chem"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.4049\/jimmunol.1001298","volume":"185","author":"Hill L.M.","year":"2010","unstructured":"Hill L.M.; Gavala M.L.; Lenertz L.Y.; Bertics P.J.; Extracellular ATP may contribute to tissue repair by rapidly stimulating purinergic receptor X7-dependent vascular endothelial growth factor release from primary human monocytes. J Immunol  2010,185(5),3028-3034","journal-title":"J Immunol"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"4946","DOI":"10.1182\/blood-2005-07-2994","volume":"107","author":"Gu B.J.","year":"2006","unstructured":"Gu B.J.; Wiley J.S.; Rapid ATP-induced release of matrix metalloproteinase 9 is mediated by the P2X7 receptor. Blood  2006,107(12),4946-4953","journal-title":"Blood"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.humpath.2017.03.019","volume":"64","author":"Qian F.","year":"2017","unstructured":"Qian F.; Xiao J.; Hu B.; Sun N.; Yin W.; Zhu J.; High expression of P2X7R is an independent postoperative indicator of poor prognosis in colorectal cancer. Hum Pathol  2017,64,61-68","journal-title":"Hum Pathol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1097\/MPA.0000000000001055","volume":"47","author":"Choi J.H.","year":"2018","unstructured":"Choi J.H.; Ji Y.G.; Ko J.J.; Cho H.J.; Lee D.H.; Activating P2X7 receptors increases proliferation of human pancreatic cancer cells via ERK1\/2 and JNK. Pancreas  2018,47(5),643-651","journal-title":"Pancreas"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"e114371","DOI":"10.1371\/journal.pone.0114371","volume":"9","author":"Qiu Y.","year":"2014","unstructured":"Qiu Y.; Li W.; Zhang H.; Liu Y.; Tian X.X.; Fang W.G.; P2X7 mediates ATP-driven invasiveness in prostate cancer cells. PLoS One  2014,9(12),e114371","journal-title":"PLoS One"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"793","DOI":"10.3389\/fphar.2020.00793","volume":"11","author":"Lara R.","year":"2020","unstructured":"Lara R.; Adinolfi E.; Harwood C.A.; Philpott M.; Barden J.A.; Di Virgilio F.; McNulty S.; P2X7 in cancer: From molecular mechanisms to therapeutics. Front Pharmacol  2020,11,793","journal-title":"Front Pharmacol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"366ra162","DOI":"10.1126\/scitranslmed.aaf8463","volume":"8","author":"Danquah W.","year":"2016","unstructured":"Danquah W.; Meyer-Schwesinger C.; Rissiek B.; Pinto C.; Serracant-Prat A.; Amadi M.; Iacenda D.; Knop J.H.; Hammel A.; Bergmann P.; Schwarz N.; Assun\u00e7\u00e3o J.; Rotthier W.; Haag F.; Tolosa E.; Bannas P.; Bou\u00e9-Grabot E.; Magnus T.; Laeremans T.; Stortelers C.; Koch-Nolte F.; Nanobodies that block gating of the P2X7 ion channel ameliorate inflammation. Sci Transl Med  2016,8(366),366ra162","journal-title":"Sci Transl Med"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"5895","DOI":"10.18632\/oncotarget.13927","volume":"8","author":"Salvestrini V.","year":"2017","unstructured":"Salvestrini V.; Orecchioni S.; Talarico G.; Reggiani F.; Mazzetti C.; Bertolini F.; Orioli E.; Adinolfi E.; Virgilio F.D.; Pezzi A.; Cavo M.; Lemoli R.M.; Curti A.; Extracellular ATP induces apoptosis through P2X7R activation in acute myeloid leukemia cells but not in normal hematopoietic stem cells. Oncotarget  2017,8(4),5895-5908","journal-title":"Oncotarget"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1016\/j.bbagen.2012.08.013","volume":"1820","author":"Souza C.O.","year":"2012","unstructured":"Souza C.O.; Santoro G.F.; Figliuolo V.R.; Nanini H.F.; de Souza H.S.P.; Castelo-Branco M.T.L.; Abalo A.A.; Paiva M.M.; Coutinho C.M.L.M.; Coutinho-Silva R.; Extracellular ATP induces cell death in human intestinal epithelial cells. Biochim Biophys Acta, Gen Subj  2012,1820(12),1867-1878","journal-title":"Biochim Biophys Acta, Gen Subj"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00441-005-1149-x","volume":"321","author":"White N.","year":"2005","unstructured":"White N.; Butler P.E.M.; Burnstock G.; Human melanomas express functional P2X7 receptors. Cell Tissue Res  2005,321(3),411-418","journal-title":"Cell Tissue Res"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1002\/jcb.22478","volume":"109","author":"Tamajusuku A.S.K.","year":"2010","unstructured":"Tamajusuku A.S.K.; Villodre E.S.; Paulus R.; Coutinho-Silva R.; Battasstini A.M.O.; Wink M.R.; Lenz G.; Characterization of ATP-induced cell death in the GL261 mouse glioma. J Cell Biochem  2010,109(5),983-991","journal-title":"J Cell Biochem"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1124\/mol.58.1.82","volume":"58","author":"Jiang L.H.","year":"2000","unstructured":"Jiang L.H.; Mackenzie A.B.; North R.A.; Surprenant A.; Brilliant blue G selectively blocks ATP-gated rat P2X(7) receptors. Mol Pharmacol  2000,58(1),82-88","journal-title":"Mol Pharmacol"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1038\/sj.bjp.0701081","volume":"120","author":"Gargett C.E.","year":"1997","unstructured":"Gargett C.E.; Wiley J.S.; The isoquinoline derivative KN-62 a potent antagonist of the P2Z-receptor of human lymphocytes. Br J Pharmacol  1997,120(8),1483-1490","journal-title":"Br J Pharmacol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/j.1476-5381.2009.00233.x","volume":"157","author":"Donnelly-Roberts D.L.","year":"2009","unstructured":"Donnelly-Roberts D.L.; Namovic M.T.; Han P.; Jarvis M.F.; Mammalian P2X7 receptor pharmacology: Comparison of recombinant mouse, rat and human P2X7 receptors. Br J Pharmacol  2009,157(7),1203-1214","journal-title":"Br J Pharmacol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/j.neuroscience.2007.03.035","volume":"146","author":"McGaraughty S.","year":"2007","unstructured":"McGaraughty S.; Chu K.L.; Namovic M.T.; Donnelly-Roberts D.L.; Harris R.R.; Zhang X.F.; Shieh C.C.; Wismer C.T.; Zhu C.Z.; Gauvin D.M.; Fabiyi A.C.; Honore P.; Gregg R.J.; Kort M.E.; Nelson D.W.; Carroll W.A.; Marsh K.; Faltynek C.R.; Jarvis M.F.; P2X7-related modulation of pathological nociception in rats. Neuroscience  2007,146(4),1817-1828","journal-title":"Neuroscience"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1124\/jpet.106.111559","volume":"319","author":"Honore P.","year":"2006","unstructured":"Honore P.; Donnelly-Roberts D.; Namovic M.T.; Hsieh G.; Zhu C.Z.; Mikusa J.P.; Hernandez G.; Zhong C.; Gauvin D.M.; Chandran P.; Harris R.; Medrano A.P.; Carroll W.; Marsh K.; Sullivan J.P.; Faltynek C.R.; Jarvis M.F.; A-740003 [N-(1-[(cyanoimino)(5-quinolinylamino) methyl]amino-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl)acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic pain in the rat. J Pharmacol Exp Ther  2006,319(3),1376-1385","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1124\/jpet.108.141853","volume":"327","author":"Broom D.C.","year":"2008","unstructured":"Broom D.C.; Matson D.J.; Bradshaw E.; Buck M.E.; Meade R.; Coombs S.; Matchett M.; Ford K.K.; Yu W.; Yuan J.; Sun S.H.; Ochoa R.; Krause J.E.; Wustrow D.J.; Cortright D.N.; Characterization of N -(Adamantan-1-ylmethyl)-5-[(3 R -aminopyrrolidin-1-yl)methyl]-2-chloro-benzamide, a P2X 7 antagonist in animal models of pain and inflammation. J Pharmacol Exp Ther  2008,327(3),620-633","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11302-011-9272-5","volume":"8","author":"Gum R.J.","year":"2012","unstructured":"Gum R.J.; Wakefield B.; Jarvis M.F.; P2X receptor antagonists for pain management: Examination of binding and physicochemical properties. Purinergic Signal  2012,8(S1),41-56","journal-title":"Purinergic Signal"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1038\/sj.bjp.0707265","volume":"151","author":"Donnelly-Roberts D.L.","year":"2007","unstructured":"Donnelly-Roberts D.L.; Jarvis M.F.; Discovery of P2X 7 receptor-selective antagonists offers new insights into P2X 7 receptor function and indicates a role in chronic pain states. Br J Pharmacol  2007,151(5),571-579","journal-title":"Br J Pharmacol"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41598-017-00732-5","volume":"7","author":"Allsopp R.C.","year":"2017","unstructured":"Allsopp R.C.; Dayl S.; Schmid R.; Evans R.J.; Unique residues in the ATP gated human P2X7 receptor define a novel allosteric binding pocket for the selective antagonist AZ10606120. Sci Rep  2017,7(1),725","journal-title":"Sci Rep"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"3123","DOI":"10.1021\/jm801528x","volume":"52","author":"Guile S.D.","year":"2009","unstructured":"Guile S.D.; Alcaraz L.; Birkinshaw T.N.; Bowers K.C.; Ebden M.R.; Furber M.; Stocks M.J.; Antagonists of the P2X(7) receptor. From lead identification to drug development. J Med Chem  2009,52(10),3123-3141","journal-title":"J Med Chem"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1016\/j.bmcl.2003.08.034","volume":"13","author":"Baxter A.","year":"2003","unstructured":"Baxter A.; Bent J.; Bowers K.; Braddock M.; Brough S.; Fagura M.; Lawson M.; McInally T.; Mortimore M.; Robertson M.; Weaver R.; Webborn P.; Hit-to-Lead studies: The discovery of potent adamantane amide P2X7 receptor antagonists. Bioorg Med Chem Lett  2003,13(22),4047-4050","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1021\/cn500054n","volume":"5","author":"Wilkinson S.M.","year":"2014","unstructured":"Wilkinson S.M.; Gunosewoyo H.; Barron M.L.; Boucher A.; McDonnell M.; Turner P.; Morrison D.E.; Bennett M.R.; McGregor I.S.; Rendina L.M.; Kassiou M.; The first CNS-active carborane: A novel P2X7 receptor antagonist with antidepressant activity. ACS Chem Neurosci  2014,5(5),335-339","journal-title":"ACS Chem Neurosci"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1021\/acschemneuro.7b00272","volume":"8","author":"Wilkinson S.M.","year":"2017","unstructured":"Wilkinson S.M.; Barron M.L.; O\u2019Brien-Brown J.; Janssen B.; Stokes L.; Werry E.L.; Chishty M.; Skarratt K.K.; Ong J.A.; Hibbs D.E.; Vugts D.J.; Fuller S.; Windhorst A.D.; Kassiou M.; Pharmacological evaluation of novel bioisosteres of an adamantanyl benzamide P2X7 Receptor antagonist. ACS Chem Neurosci  2017,8(11),2374-2380","journal-title":"ACS Chem Neurosci"},{"key":"ref=96","author":"Dombroski M.A.","year":"2004","unstructured":"Dombroski M.A.; Duplantier A.J.; Subramanyam C.; Benzamide inhibitors of the P2X7 receptor. PCT Appl N WO\t2004\/099146  2004","journal-title":"PCT Appl N WO\t2004\/099146"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1016\/j.bmcl.2010.03.094","volume":"20","author":"Chen X.","year":"2010","unstructured":"Chen X.; Pierce B.; Naing W.; Grapperhaus M.L.; Phillion D.P.; Discovery of 2-chloro-N-((4,4-difluoro-1-hydroxycyclohexyl)methyl)-5-(5-fluoropyrimidin-2-yl)benzamide as a potent and CNS penetrable P2X7 receptor antagonist. Bioorg Med Chem Lett  2010,20(10),3107-3111","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1016\/j.bmcl.2011.04.077","volume":"21","author":"Duplantier A.J.","year":"2011","unstructured":"Duplantier A.J.; Dombroski M.A.; Subramanyam C.; Beaulieu A.M.; Chang S.P.; Gabel C.A.; Jordan C.; Kalgutkar A.S.; Kraus K.G.; Labasi J.M.; Mussari C.; Perregaux D.G.; Shepard R.; Taylor T.J.; Trevena K.A.; Whitney-Pickett C.; Yoon K.; Optimization of the physicochemical and pharmacokinetic attributes in a 6-azauracil series of P2X7 receptor antagonists leading to the discovery of the clinical candidate CE-224,535. Bioorg Med Chem Lett  2011,21(12),3708-3711","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.1016\/j.bmcl.2011.06.117","volume":"21","author":"Subramanyam C.","year":"2011","unstructured":"Subramanyam C.; Duplantier A.J.; Dombroski M.A.; Chang S.P.; Gabel C.A.; Whitney-Pickett C.; Perregaux D.G.; Labasi J.M.; Yoon K.; Shepard R.M.; Fisher M.; Discovery, synthesis and SAR of azinyl- and azolylbenzamides antagonists of the P2X7 receptor. Bioorg Med Chem Lett  2011,21(18),5475-5479","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"720","DOI":"10.3899\/jrheum.110874","volume":"39","author":"Stock T.C.","year":"2012","unstructured":"Stock T.C.; Bloom B.J.; Wei N.; Ishaq S.; Park W.; Wang X.; Gupta P.; Mebus C.A.; Efficacy and safety of CE-224,535, an antagonist of P2X7 receptor, in treatment of patients with rheumatoid arthritis inadequately controlled by methotrexate. J Rheumatol  2012,39(4),720-727","journal-title":"J Rheumatol"},{"key":"ref=101","author":"Guile S.D.","year":"2008","unstructured":"Guile S.D.; Ebden M.;  Quinoline derivatives for the treatment of inflammatory diseases  2008","journal-title":"Quinoline derivatives for the treatment of inflammatory diseases"},{"key":"ref=102","author":"Guile S.D.","year":"2009","unstructured":"Guile S.D.; Thompson T.;  A quinoline derivative acting as a P2X7-receptor antagonist  2009","journal-title":"A quinoline derivative acting as a P2X7-receptor antagonist"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.bmcl.2019.04.033","volume":"29","author":"Xiao Y.","year":"2019","unstructured":"Xiao Y.; Karra S.; Goutopoulos A.; Morse N.T.; Zhang S.; Dhanabal M.; Tian H.; Seenisamy J.; Jayadevan J.; Caldwell R.; Potnick J.; Bleich M.; Chekler E.; Sherer B.; Sriraman V.; Synthesis and SAR development of quinoline analogs as novel P2X7 receptor antagonists. Bioorg Med Chem Lett  2019,29(13),1660-1664","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1021\/ml400040v","volume":"4","author":"Letavic M.A.","year":"2013","unstructured":"Letavic M.A.; Lord B.; Bischoff F.; Hawryluk N.A.; Pieters S.; Rech J.C.; Sales Z.; Velter A.I.; Ao H.; Bonaventure P.; Contreras V.; Jiang X.; Morton K.L.; Scott B.; Wang Q.; Wickenden A.D.; Carruthers N.I.; Bhattacharya A.; Synthesis and pharmacological characterization of two novel, brain penetrating P2X7 antagonists. ACS Med Chem Lett  2013,4(4),419-422","journal-title":"ACS Med Chem Lett"},{"key":"ref=105","author":"Kilburn J.P.","year":"2014","unstructured":"Kilburn J.P.; Rasmussen L.K.; Jessing M.; Eldemenky E.M.; Chen B.; Jiang Y.; Hopper A.T.;  Benzamides. PCT\nAppl. N.   2014"},{"key":"ref=106","author":"Kilburn J.P.","year":"2014","unstructured":"Kilburn J.P.; Rasmussen L.K.; Jessing M.; Eldemenky E.M.; Chen B.; Jiang Y. N N;  -(2-(cyclic\namine)ethyl)benzamide derivatives as P2X7 inhibitors PCT\nAppl N  2014","journal-title":"-(2-(cyclic\namine)ethyl)benzamide derivatives as P2X7 inhibitors PCT\nAppl N"},{"key":"ref=107","author":"Kilburn J.P.","year":"2014","unstructured":"Kilburn J.P.; Hopper A.T.; Juhl M.;  Inhibitor of the p2x7 receptor  2014","journal-title":"Inhibitor of the p2x7 receptor"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"4891","DOI":"10.1021\/acs.jmedchem.0c02249","volume":"64","author":"Hopper A.T.","year":"2021","unstructured":"Hopper A.T.; Juhl M.; Hornberg J.; Badolo L.; Kilburn J.P.; Thougaard A.; Smagin G.; Song D.; Calice L.; Menon V.; Dale E.; Zhang H.; Cajina M.; Nattini M.E.; Gandhi A.; Grenon M.; Jones K.; Khayrullina T.; Chandrasena G.; Thomsen C.; Zorn S.H.; Brodbeck R.; Poda S.B.; Staal R.; M\u00f6ller T.; Synthesis and characterization of the novel rodent-active and CNS-Penetrant P2X7 receptor antagonist Lu AF27139. J Med Chem  2021,64(8),4891-4902","journal-title":"J Med Chem"},{"key":"ref=109","author":"Love C.J.","year":"2009","unstructured":"Love C.J.; Leenaerts J.E.; Cooymans L.P.; Lebsack A.D.; Branstetter B.J.; Rech J.C.; Gleason E.A.; Venable J.D.; Wiener D.; Smith D.M.; Breitenbucher J.G.; PCT Appl. N.\n  2009"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1016\/j.bmcl.2016.08.029","volume":"26","author":"Rech J.C.","year":"2016","unstructured":"Rech J.C.; Bhattacharya A.; Branstetter B.J.; Love C.J.; Leenaerts J.E.; Cooymans L.P.; Eckert W.A.; Ao H.; Wang Q.; Chaplan S.R.; Wickenden A.D.; Lebsack A.D.; Breitenbucher J.G.; The discovery and preclinical characterization of 6-chloro- N -(2-(4,4-difluoropiperidin-1-yl)-2-(2-(trifluoromethyl)pyrimidin-5-yl)ethyl)quinoline-5-carboxamide based P2X7 antagonists. Bioorg Med Chem Lett  2016,26(19),4781-4784","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=111","author":"Dean D.K.","year":"2010","unstructured":"Dean D.K.; Munoz-Muriedas J.; Sime M.; Steadman J.G.A.; Thewlis R.E.A.; Trani G.; Walter D.S.;  5,6,7,8-\tTetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as\nP2X7 modulators PCT Appl N  2010","journal-title":"5,6,7,8-\tTetrahydro[1,2,4]triazolo[4,3-a]pyrazine derivatives as\nP2X7 modulators PCT Appl N"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1016\/j.bmcl.2015.06.004","volume":"25","author":"Rudolph D.A.","year":"2015","unstructured":"Rudolph D.A.; Alcazar J.; Ameriks M.K.; Anton A.B.; Ao H.; Bonaventure P.; Carruthers N.I.; Chrovian C.C.; De Angelis M.; Lord B.; Rech J.C.; Wang Q.; Bhattacharya A.; Andres J.I.; Letavic M.A.; Novel methyl substituted 1-(5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanones are P2X7 antagonists. Bioorg Med Chem Lett  2015,25(16),3157-3163","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1021\/acschemneuro.5b00303","volume":"7","author":"Chrovian C.C.","year":"2016","unstructured":"Chrovian C.C.; Soyode-Johnson A.; Ao H.; Bacani G.M.; Carruthers N.I.; Lord B.; Nguyen L.; Rech J.C.; Wang Q.; Bhattacharya A.; Letavic M.A.; Novel phenyl-substituted 5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazine P2X7 antagonists with robust target engagement in rat brain. ACS Chem Neurosci  2016,7(4),490-497","journal-title":"ACS Chem Neurosci"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1021\/acsmedchemlett.5b00089","volume":"6","author":"Savall B.M.","year":"2015","unstructured":"Savall B.M.; Wu D.; De Angelis M.; Carruthers N.I.; Ao H.; Wang Q.; Lord B.; Bhattacharya A.; Letavic M.A.; Synthesis, SAR, and pharmacological characterization of brain penetrant P2X7 receptor antagonists. ACS Med Chem Lett  2015,6(6),671-676","journal-title":"ACS Med Chem Lett"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1021\/acs.jmedchem.7b00408","volume":"60","author":"Letavic M.A.","year":"2017","unstructured":"Letavic M.A.; Savall B.M.; Allison B.D.; Aluisio L.; Andres J.I.; De Angelis M.; Ao H.; Beauchamp D.A.; Bonaventure P.; Bryant S.; Carruthers N.I.; Ceusters M.; Coe K.J.; Dvorak C.A.; Fraser I.C.; Gelin C.F.; Koudriakova T.; Liang J.; Lord B.; Lovenberg T.W.; Otieno M.A.; Schoetens F.; Swanson D.M.; Wang Q.; Wickenden A.D.; Bhattacharya A.; 4-Methyl-6,7-dihydro-4 H -triazolo[4,5- c]pyridine-Based P2X7 receptor antagonists: optimization of pharmacokinetic properties leading to the identification of a clinical candidate. J Med Chem  2017,60(11),4559-4572","journal-title":"J Med Chem"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"8535","DOI":"10.1021\/acs.jmedchem.6b00989","volume":"59","author":"Swanson D.M.","year":"2016","unstructured":"Swanson D.M.; Savall B.M.; Coe K.J.; Schoetens F.; Koudriakova T.; Skaptason J.; Wall J.; Rech J.; Deng X.; De Angelis M.; Everson A.; Lord B.; Wang Q.; Ao H.; Scott B.; Sepassi K.; Lovenberg T.W.; Carruthers N.I.; Bhattacharya A.; Letavic M.A.; Identification of (R)-(2-Chloro-3-(trifluoromethyl)phenyl)(1-(5-fluoropyridin-2-yl)-4-methyl-6,7-dihydro-1 H -imidazo[4,5- c]pyridin-5(4 H)-yl)methanone (JNJ 54166060), a small molecule antagonist of the P2X7 receptor. J Med Chem  2016,59(18),8535-8548","journal-title":"J Med Chem"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1021\/acschemneuro.5b00304","volume":"7","author":"Ziff J.","year":"2016","unstructured":"Ziff J.; Rudolph D.A.; Stenne B.; Koudriakova T.; Lord B.; Bonaventure P.; Lovenberg T.W.; Carruthers N.I.; Bhattacharya A.; Letavic M.A.; Shireman B.T.; Substituted 5,6-(Dihydropyrido[3,4- d]pyrimidin-7(8 H)-yl)-methanones as P2X7 antagonists. ACS Chem Neurosci  2016,7(4),498-504","journal-title":"ACS Chem Neurosci"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bmcl.2015.12.052","volume":"26","author":"Ameriks M.K.","year":"2016","unstructured":"Ameriks M.K.; Ao H.; Carruthers N.I.; Lord B.; Ravula S.; Rech J.C.; Savall B.M.; Wall J.L.; Wang Q.; Bhattacharya A.; Letavic M.A.; Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3- a]pyrazin-8(5 H)-one P2X7 receptor antagonists. Bioorg Med Chem Lett  2016,26(2),257-261","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=119","author":"Carroll W.A.","year":"2005","unstructured":"Carroll W.A.; Perez-Medrano A.; Florjancic A.S.; Nelson D.W.; Peddi S.; Li T.; Bunnelle E.M.; Hirst G.C.; Li B.;  Amino-tetrazoles analogues and methods of use  2005","journal-title":"Amino-tetrazoles analogues and methods of use"},{"key":"ref=120","author":"Carroll W.A.","year":"2007","unstructured":"Carroll W.A.;  P2X7 receptor antagonists and methods of use  2007","journal-title":"P2X7 receptor antagonists and methods of use"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"8413","DOI":"10.1021\/acs.jmedchem.5b00365","volume":"58","author":"Lopez-Tapia F.","year":"2015","unstructured":"Lopez-Tapia F.; Walker K.A.M.; Brotherton-Pleiss C.; Caroon J.; Nitzan D.; Lowrie L.; Gleason S.; Zhao S.H.; Berger J.; Cockayne D.; Phippard D.; Suttmann R.; Fitch W.L.; Bourdet D.; Rege P.; Huang X.; Broadbent S.; Dvorak C.; Zhu J.; Wagner P.; Padilla F.; Loe B.; Jahangir A.; Alker A.; Novel series of dihydropyridinone P2X7 receptor antagonists. J Med Chem  2015,58(21),8413-8426","journal-title":"J Med Chem"},{"key":"ref=122","author":"Beswick P.J.","year":"2007","unstructured":"Beswick P.J.; Chambers L.J.; Davies D.J.; Dean D.K.; Demont E.H.; Susan Roomans S.; Walter D.S. N N; (phenylmethyl)-2-(1H-pyrazol-4-yl) acetamide derivatives as P2X7 antagonists for the treatment of pain, inflammation\nand neurodegeneration. PCT Appl. N.  2007"},{"key":"ref=123","author":"Beswick P.J.","year":"2008","unstructured":"Beswick P.J.; Dean D.K.; Walter D.S.;  Pyrazole derivatives as P2X7 modulators PCT Appl N PCT App N  2008","journal-title":"Pyrazole derivatives as P2X7 modulators PCT Appl N PCT App N"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"3161","DOI":"10.1016\/j.bmcl.2010.03.096","volume":"20","author":"Chambers L.J.","year":"2010","unstructured":"Chambers L.J.; Stevens A.J.; Moses A.P.; Michel A.D.; Walter D.S.; Davies D.J.; Livermore D.G.; Fonfria E.; Demont E.H.; Vimal M.; Theobald P.J.; Beswick P.J.; Gleave R.J.; Roman S.A.; Senger S.; Synthesis and structure\u2013activity relationships of a series of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor. Bioorg Med Chem Lett  2010,20(10),3161-3164","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1016\/j.bmcl.2010.05.107","volume":"20","author":"Beswick P.J.","year":"2010","unstructured":"Beswick P.J.; Billinton A.; Chambers L.J.; Dean D.K.; Fonfria E.; Gleave R.J.; Medhurst S.J.; Michel A.D.; Moses A.P.; Patel S.; Roman S.A.; Roomans S.; Senger S.; Stevens A.J.; Walter D.S.; Structure\u2013activity relationships and in vivo activity of (1H-pyrazol-4-yl)acetamide antagonists of the P2X7 receptor. Bioorg Med Chem Lett  2010,20(15),4653-4656","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"4951","DOI":"10.1016\/j.bmcl.2010.05.018","volume":"20","author":"Gleave R.J.","year":"2010","unstructured":"Gleave R.J.; Walter D.S.; Beswick P.J.; Fonfria E.; Michel A.D.; Roman S.A.; Tang S.P.; Synthesis and biological activity of a series of tetrasubstituted-imidazoles as P2X7 antagonists. Bioorg Med Chem Lett  2010,20(16),4951-4954","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"5080","DOI":"10.1016\/j.bmcl.2010.07.033","volume":"20","author":"Abdi M.H.","year":"2010","unstructured":"Abdi M.H.; Beswick P.J.; Billinton A.; Chambers L.J.; Charlton A.; Collins S.D.; Collis K.L.; Dean D.K.; Fonfria E.; Gleave R.J.; Lejeune C.L.; Livermore D.G.; Medhurst S.J.; Michel A.D.; Moses A.P.; Page L.; Patel S.; Roman S.A.; Senger S.; Slingsby B.; Steadman J.G.A.; Stevens A.J.; Walter D.S.; Discovery and structure\u2013activity relationships of a series of pyroglutamic acid amide antagonists of the P2X7 receptor. Bioorg Med Chem Lett  2010,20(17),5080-5084","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1111\/j.1365-2125.2012.04320.x","volume":"75","author":"Ali Z.","year":"2013","unstructured":"Ali Z.; Laurijssens B.; Ostenfeld T.; McHugh S.; Stylianou A.; Scott-Stevens P.; Hosking L.; Dewit O.; Richardson J.C.; Chen C.; Pharmacokinetic and pharmacodynamic profiling of a P2X7 receptor allosteric modulator GSK1482160 in healthy human subjects. Br J Clin Pharmacol  2013,75(1),197-207","journal-title":"Br J Clin Pharmacol"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"6370","DOI":"10.1016\/j.bmcl.2010.09.101","volume":"20","author":"Abberley L.","year":"2010","unstructured":"Abberley L.; Bebius A.; Beswick P.J.; Billinton A.; Collis K.L.; Dean D.K.; Fonfria E.; Gleave R.J.; Medhurst S.J.; Michel A.D.; Moses A.P.; Patel S.; Roman S.A.; Scoccitti T.; Smith B.; Steadman J.G.A.; Walter D.S.; Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidine-carboxamide antagonists of the P2X7 receptor. Bioorg Med Chem Lett  2010,20(22),6370-6374","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.ejpain.2005.08.003","volume":"10","author":"Wilson A.W.","year":"2006","unstructured":"Wilson A.W.; Medhurst S.J.; Dixon C.I.; Bontoft N.C.; Winyard L.A.; Brackenborough K.T.; Alba J.; Clarke C.J.; Gunthorpe M.J.; Hicks G.A.; Bountra C.; McQueen D.S.; Chessell I.P.; An animal model of chronic inflammatory pain: Pharmacological and temporal differentiation from acute models. Eur J Pain  2006,10(6),537-549","journal-title":"Eur J Pain"},{"key":"ref=131","author":"Betschmann P.","year":"2008","unstructured":"Betschmann P.; Carroll W.A.; Ericsson A.M.; Fix-Stenzel S.R.; Friedman M.; Hirst G.C.; Josephsohn N.S.; Li B.; Perez-Medrano A.; Morytko M.J.; Rafferty P.; Chen H.; Piperazines as P2X7 antagonists. PCT Appl N  2008","journal-title":"PCT Appl N"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1016\/j.bmcl.2008.01.094","volume":"18","author":"Morytko M.J.","year":"2008","unstructured":"Morytko M.J.; Betschmann P.; Woller K.; Ericsson A.; Chen H.; Donnelly-Roberts D.L.; Namovic M.T.; Jarvis M.F.; Carroll W.A.; Rafferty P.; Synthesis and in vitro activity of N\u2032-cyano-4-(2-phenylacetyl)-N-o-tolylpiperazine-1-carboximidamide P2X7 antagonists. Bioorg Med Chem Lett  2008,18(6),2093-2096","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"113838","DOI":"10.1016\/j.ejmech.2021.113838","volume":"226","author":"Patberg M.","year":"2021","unstructured":"Patberg M.; Isaak A.; F\u00fcsser F.; Ortiz Zacar\u00edas N.V.; Vinnenberg L.; Schulte J.; Michetti L.; Grey L.; van der Horst C.; Hundehege P.; Koch O.; Heitman L.H.; Budde T.; Junker A.; Piperazine squaric acid diamides, a novel class of allosteric P2X7 receptor antagonists. Eur J Med Chem  2021,226,113838","journal-title":"Eur J Med Chem"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ejmech.2017.02.060","volume":"130","author":"O\u2019Brien-Brown J.","year":"2017","unstructured":"O\u2019Brien-Brown J.; Jackson A.; Reekie T.A.; Barron M.L.; Werry E.L.; Schiavini P.; McDonnell M.; Munoz L.; Wilkinson S.; Noll B.; Wang S.; Kassiou M.; Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists. Eur J Med Chem  2017,130,433-439","journal-title":"Eur J Med Chem"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1021\/acs.jmedchem.0c02145","volume":"64","author":"Calzaferri F.","year":"2021","unstructured":"Calzaferri F.; Narros-Fern\u00e1ndez P.; de Pascual R.; de Diego A.M.G.; Nicke A.; Egea J.; Garc\u00eda A.G.; de los R\u00edos C.; Synthesis and pharmacological evaluation of novel non-nucleotide purine derivatives as P2X7 antagonists for the treatment of neuroinflammation. J Med Chem  2021,64(4),2272-2290","journal-title":"J Med Chem"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.ejmech.2017.10.033","volume":"143","author":"Faria R.X.","year":"2018","unstructured":"Faria R.X.; Oliveira F.H.; Salles J.P.; Oliveira A.S.; von Ranke N.L.; Bello M.L.; Rodrigues C.R.; Castro H.C.; Louvis A.R.; Martins D.L.; Ferreira V.F.; 1,4-Naphthoquinones potently inhibiting P2X7 receptor activity. Eur J Med Chem  2018,143,1361-1372","journal-title":"Eur J Med Chem"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1016\/j.bmc.2018.11.036","volume":"27","author":"Pacheco P.A.F.","year":"2019","unstructured":"Pacheco P.A.F.; Galv\u00e3o R.M.S.; Faria A.F.M.; Von Ranke N.; Rangel M.S.; Ribeiro T.M.; Bello M.; Rodrigues C.R.; Ferreira V.F.; da Rocha D.R.; Faria R.X.; 8-Hydroxy-2-(1H-1,2,3-triazol-1-yl)-1,4-naphtoquinone derivatives inhibited P2X7 Receptor-Induced dye uptake into murine macrophages. Bioorg Med Chem  2019,27(8),1449-1455","journal-title":"Bioorg Med Chem"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"115975","DOI":"10.1016\/j.bmc.2020.115975","volume":"31","author":"Pislyagin E.","year":"2021","unstructured":"Pislyagin E.; Kozlovskiy S.; Menchinskaya E.; Chingizova E.; Likhatskaya G.; Gorpenchenko T.; Sabutski Y.; Polonik S.; Aminin D.; Synthetic 1,4-Naphthoquinones inhibit P2X7 receptors in murine neuroblastoma cells. Bioorg Med Chem  2021,31,115975","journal-title":"Bioorg Med Chem"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1021\/jm500324g","volume":"58","author":"Park J.H.","year":"2015","unstructured":"Park J.H.; Lee G.E.; Lee S.D.; Hien T.T.; Kim S.; Yang J.W.; Cho J.H.; Ko H.; Lim S.C.; Kim Y.G.; Kang K.W.; Kim Y.C.; Discovery of novel 2,5-dioxoimidazolidine-based P2X(7) receptor antagonists as constrained analogues of KN62. J Med Chem  2015,58(5),2114-2134","journal-title":"J Med Chem"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejmech.2015.10.036","volume":"106","author":"Park J.H.","year":"2015","unstructured":"Park J.H.; Lee G.E.; Lee S.D.; Ko H.; Kim Y.C.; Structure\u2013activity relationship studies of pyrimidine-2,4-dione derivatives as potent P2X7 receptor antagonists. Eur J Med Chem  2015,106,180-193","journal-title":"Eur J Med Chem"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"3805","DOI":"10.1016\/j.bmcl.2011.04.034","volume":"21","author":"Matasi J.J.","year":"2011","unstructured":"Matasi J.J.; Brumfield S.; Tulshian D.; Czarnecki M.; Greenlee W.; Garlisi C.G.; Qiu H.; Devito K.; Chen S.C.; Sun Y.; Bertorelli R.; Geiss W.; Le V.D.; Martin G.S.; Vellekoop S.A.; Haber J.; Allard M.L.; Synthesis and SAR development of novel P2X7 receptor antagonists for the treatment of pain: Part 1. Bioorg Med Chem Lett  2011,21(12),3805-3808","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"114162","DOI":"10.1016\/j.ejmech.2022.114162","volume":"231","author":"Mahmood A.","year":"2022","unstructured":"Mahmood A.; Ali Shah S.J.; Iqbal J.; Design and synthesis of adamantane-1-carbonyl thiourea derivatives as potent and selective inhibitors of h-P2X4 and h-P2X7 receptors: An emerging therapeutic tool for treatment of inflammation and neurological disorders. Eur J Med Chem  2022,231,114162","journal-title":"Eur J Med Chem"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrd1007","volume":"2","author":"Rudin M.","year":"2003","unstructured":"Rudin M.; Weissleder R.; Molecular imaging in drug discovery and development. Nat Rev Drug Discov  2003,2(2),123-131","journal-title":"Nat Rev Drug Discov"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.2174\/0929867323666160418114826","volume":"23","author":"Pike V.W.","year":"2016","unstructured":"Pike V.W.; Considerations in the development of reversibly binding PET radioligands for brain imaging. Curr Med Chem  2016,23(18),1818-1869","journal-title":"Curr Med Chem"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"607","DOI":"10.3390\/molecules23030607","volume":"23","author":"Janssen B.","year":"2018","unstructured":"Janssen B.; Vugts D.; Windhorst A.; Mach R.; PET imaging of microglial activation beyond targeting TSPO. Molecules  2018,23(3),607","journal-title":"Molecules"},{"key":"ref=146","first-page":"S277","volume":"58","author":"Janssen B.","year":"2015","unstructured":"Janssen B.; Ory D.; Wilkinson S.M.; Vugts D.J.; Kooijman E.; Verbeek J.; Funke U.; Molenaar G.T.; Kruijer P.S.; Lammertsma A.A.; Kassiou M.; Bormans G.; Windhorst A.D.; Initial evaluation of P2X7R antagonists [11C]A-740003 and [11C]SMW64-D16 as PET tracers of microglialactivation in neuroinflammation. J Labelled Comp Radiopharm  2015,58,S277","journal-title":"J Labelled Comp Radiopharm"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1038\/s41598-018-24814-0","volume":"8","author":"Janssen B.","year":"2018","unstructured":"Janssen B.; Vugts D.J.; Wilkinson S.M.; Ory D.; Chalon S.; Hoozemans J.J.M.; Schuit R.C.; Beaino W.; Kooijman E.J.M.; van den Hoek J.; Chishty M.; Dom\u00e9n\u00e9 A.; Van der Perren A.; Villa A.; Maggi A.; Molenaar G.T.; Funke U.; Shevchenko R.V.; Baekelandt V.; Bormans G.; Lammertsma A.A.; Kassiou M.; Windhorst A.D.; Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation. Sci Rep  2018,8(1),6580","journal-title":"Sci Rep"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s00259-019-04550-x","volume":"47","author":"Hagens M.H.J.","year":"2020","unstructured":"Hagens M.H.J.; Golla S.S.V.; Janssen B.; Vugts D.J.; Beaino W.; Windhorst A.D.; O\u2019Brien-Brown J.; Kassiou M.; Schuit R.C.; Schwarte L.A.; de Vries H.E.; Killestein J.; Barkhof F.; van Berckel B.N.M.; Lammertsma A.A.; The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: A first-in man study. Eur J Nucl Med Mol Imaging  2020,47(2),379-389","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"458","DOI":"10.2967\/jnumed.116.181354","volume":"58","author":"Territo P.R.","year":"2017","unstructured":"Territo P.R.; Meyer J.A.; Peters J.S.; Riley A.A.; McCarthy B.P.; Gao M.; Wang M.; Green M.A.; Zheng Q.H.; Hutchins G.D.; Characterization of 11C-GSK1482160 for targeting the P2X7 receptor as a biomarker for neuroinflammation. J Nucl Med  2017,58(3),458-465","journal-title":"J Nucl Med"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/MNM.0000000000000660","volume":"38","author":"Han J.","year":"2017","unstructured":"Han J.; Liu H.; Liu C.; Jin H.; Perlmutter J.S.; Egan T.M.; Tu Z.; Pharmacologic characterizations of a P2X7 receptor-specific radioligand, [11C]GSK1482160 for neuroinflammatory response. Nucl Med Commun  2017,38(5),372-382","journal-title":"Nucl Med Commun"},{"key":"ref=151","first-page":"1009","volume":"59","author":"Green M.","year":"2018","unstructured":"Green M.; Hutchins G.; Fletcher J.; Territo W.; Polson H.; Trussel H.; Wissman C.; Zheng Q-H.; Gao M.; Wang M.; Glick-Wilson B.; Distribution of the P2X7-receptor-targeted [11C]GSK1482160 radiopharmaceutical in normal human subjects. J Nucl Med  2018,59(Suppl. 1),1009","journal-title":"J Nucl Med"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.bmcl.2019.04.018","volume":"29","author":"Gao M.","year":"2019","unstructured":"Gao M.; Wang M.; Meyer J.A.; Territo P.R.; Hutchins G.D.; Zarrinmayeh H.; Zheng Q.H.; Synthesis and in vitro biological evaluation of new P2X7R radioligands [11C]halo-GSK1482160 analogs. Bioorg Med Chem Lett  2019,29(12),1476-1480","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.2967\/jnumed.115.169995","volume":"57","author":"Ory D.","year":"2016","unstructured":"Ory D.; Celen S.; Gijsbers R.; Van Den Haute C.; Postnov A.; Koole M.; Vandeputte C.; Andr\u00e9s J.I.; Alcazar J.; De Angelis M.; Langlois X.; Bhattacharya A.; Schmidt M.; Letavic M.A.; Vanduffel W.; Van Laere K.; Verbruggen A.; Debyser Z.; Bormans G.; Preclinical evaluation of a P2X7 receptor-selective radiotracer: PET studies in a rat model with local overexpression of the human P2X7 receptor and in nonhuman primates. J Nucl Med  2016,57(9),1436-1441","journal-title":"J Nucl Med"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.1007\/s00259-019-04369-6","volume":"46","author":"Van Weehaeghe D.","year":"2019","unstructured":"Van Weehaeghe D.; Koole M.; Schmidt M.E.; Deman S.; Jacobs A.H.; Souche E.; Serdons K.; Sunaert S.; Bormans G.; Vandenberghe W.; Van Laere K.; [11C]JNJ54173717, a novel P2X7 receptor radioligand as marker for neuroinflammation: human biodistribution, dosimetry, brain kinetic modelling and quantification of brain P2X7 receptors in patients with Parkinson\u2019s disease and healthy volunteers. Eur J Nucl Med Mol Imaging  2019,46(10),2051-2064","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13550-017-0275-2","volume":"7","author":"Fantoni E.R.","year":"2017","unstructured":"Fantoni E.R.; Dal Ben D.; Falzoni S.; Di Virgilio F.; Lovestone S.; Gee A.; Design, synthesis and evaluation in an LPS rodent model of neuroinflammation of a novel 18F-labelled PET tracer targeting P2X7. EJNMMI Res  2017,7(1),31","journal-title":"EJNMMI Res"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2967\/jnumed.118.216747","volume":"60","author":"Koole M.","year":"2019","unstructured":"Koole M.; Schmidt M.E.; Hijzen A.; Ravenstijn P.; Vandermeulen C.; Van Weehaeghe D.; Serdons K.; Celen S.; Bormans G.; Ceusters M.; Zhang W.; Van Nueten L.; Kolb H.; de Hoon J.; Van Laere K.; 18F-JNJ-64413739, a novel PET ligand for the P2X7 ion channel: Radiation dosimetry, kinetic modeling, test-retest variability, and occupancy of the P2X7 antagonist JNJ-54175446. J Nucl Med  2019,60(5),683-690","journal-title":"J Nucl Med"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"16172","DOI":"10.1038\/s41598-021-95715-y","volume":"11","author":"Mertens N.","year":"2021","unstructured":"Mertens N.; Schmidt M.E.; Hijzen A.; Van Weehaeghe D.; Ravenstijn P.; Depre M.; de Hoon J.; Van Laere K.; Koole M.; Minimally invasive quantification of cerebral P2X7R occupancy using dynamic [18F]JNJ-64413739 PET and MRA-driven image derived input function. Sci Rep  2021,11(1),16172","journal-title":"Sci Rep"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/epi.17484","volume":"64","author":"Morgan J.","year":"2023","unstructured":"Morgan J.; Moreno O.; Alves M.; Baz Z.; Men\u00e9ndez M\u00e9ndez A.; Leister H.; Melia C.; Smith J.; Visekruna A.; Nicke A.; Bhattacharya A.; Ceusters M.; Henshall D.C.; G\u00f3mez-Vallejo V.; Llop J.; Engel T.; Increased uptake of the P2X7 receptor radiotracer18 F\u2010JNJ \u201064413739 in the brain and peripheral organs according to the severity of status epilepticus in male mice. Epilepsia  2023,64(2),511-523","journal-title":"Epilepsia"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"930","DOI":"10.2967\/jnumed.118.222547","volume":"60","author":"Fu Z.","year":"2019","unstructured":"Fu Z.; Lin Q.; Hu B.; Zhang Y.; Chen W.; Zhu J.; Zhao Y.; Choi H.S.; Shi H.; Cheng D.; P2X7 PET radioligand 18F-PTTP for differentiation of lung tumor from inflammation. J Nucl Med  2019,60(7),930-936","journal-title":"J Nucl Med"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230403094538","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/215398\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867330666230403094538","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T17:01:06Z","timestamp":1708621266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/215398\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":159,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867330666230403094538","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-08-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-27","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}